enGene (NASDAQ:ENGN – Get Free Report) is one of 449 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare enGene to similar businesses based on the strength of its analyst recommendations, dividends, risk, earnings, profitability, institutional ownership and valuation.
Valuation & Earnings
This table compares enGene and its rivals top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
enGene | N/A | $104.74 million | -3.94 |
enGene Competitors | $159.28 million | -$18.96 million | -57.87 |
enGene’s rivals have higher revenue, but lower earnings than enGene. enGene is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Analyst Recommendations
This is a breakdown of current ratings and target prices for enGene and its rivals, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
enGene | 0 | 0 | 6 | 0 | 3.00 |
enGene Competitors | 755 | 2455 | 5770 | 67 | 2.57 |
enGene presently has a consensus target price of $34.40, indicating a potential upside of 435.83%. As a group, “Biotechnology” companies have a potential upside of 16.95%. Given enGene’s stronger consensus rating and higher probable upside, research analysts plainly believe enGene is more favorable than its rivals.
Profitability
This table compares enGene and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
enGene | N/A | -63.25% | -5.65% |
enGene Competitors | -11,569.30% | -124.58% | -24.31% |
Insider and Institutional Ownership
64.2% of enGene shares are owned by institutional investors. Comparatively, 31.5% of shares of all “Biotechnology” companies are owned by institutional investors. 13.7% of enGene shares are owned by company insiders. Comparatively, 22.6% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Dividends
enGene pays an annual dividend of $1.58 per share and has a dividend yield of 24.6%. enGene pays out -97.0% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 3.1% and pay out 5,072.0% of their earnings in the form of a dividend. enGene is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.
Summary
enGene beats its rivals on 11 of the 15 factors compared.
enGene Company Profile
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.